May 12, 2023
Otsuka Pharmaceutical and Lundbeck said on May 11 that they have won US approval for a label expansion for their atypical antipsychotic Rexulti (brexpiprazole), making it the country’s first drug indicated for agitation associated with Alzheimer’s dementia (AAD). The label...read more